Icsm Avoid Tt For Weight Loss

---
name: icsm-avoid-tt-for-weight-loss
description: The skill advises against using testosterone therapy alone for weight loss or cardio-metabolic improvement. It triggers when a clinician considers prescribing testosterone for obesity or diabetes and questions whether testosterone alone will aid weight loss or improve metabolic parameters.
---

# Avoid testosterone therapy alone for weight loss or cardio-metabolic improvement

## STEP 1 — Gather Information
Collect morning fasting total testosterone (tT), symptoms of hypogonadism (low libido, fatigue, erectile dysfunction), weight/BMI, waist circumference, HbA1c, fasting glucose, lipid profile, and presence of diabetes or metabolic syndrome.

## STEP 2 — Rule In / Rule Out
Is hypogonadism confirmed (tT <12 nmol/L plus ≥1 hypogonadal symptom)? If no, rule out testosterone therapy; if yes, proceed.

## STEP 3 — Classify or Stratify
Is the primary clinical goal weight loss or cardio‑metabolic improvement (rather than sexual dysfunction, fatigue, or other hypogonadal symptoms)? If yes, classify as “weight‑loss/metabolic goal”; if no, classify as “symptom‑directed goal”.

## STEP 4 — Decide
For weight‑loss/metabolic goal: avoid testosterone monotherapy; recommend intensive lifestyle intervention, consider GLP‑1RA or other glucose‑lowering agents, and reassess after 3 months. For symptom‑directed goal: testosterone therapy may be considered to alleviate hypogonadal symptoms, not for weight loss.

## Clinical Guardrails / Mimics / Pitfalls
Do not prescribe testosterone solely for weight loss or HbA1c improvement; do not ignore lifestyle modification; avoid testosterone in eugonadal men; monitor hematocrit and polycythemia; do not use testosterone as a substitute for proven metabolic therapies.

## Concrete Clinical Example
A 55‑year‑old man with BMI 34, HbA1c 7.2%, tT 9 nmol/L, low libido and fatigue asks if testosterone will help him lose weight. He meets criteria for hypogonadism but his primary request is weight loss. The skill advises against testosterone monotherapy; instead, prescribe intensive lifestyle changes, consider a GLP‑1RA, and re‑evaluate symptoms after 3 months before considering testosterone for symptom relief.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036